# A Dose Finding Study Of A New Medication, PF-00337210 That Will Possibly Decrease Blood Supply To Tumors

> **NCT01105533** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 46 (actual)

## Conditions studied

- Neoplasm

## Interventions

- **DRUG:** PF-00337210
- **DRUG:** PF-00337210
- **DRUG:** PF-00337210
- **DRUG:** PF-00337210
- **DRUG:** PF-00337210
- **DRUG:** PF-00337210
- **DRUG:** PF-00337210
- **DRUG:** PF-00337210
- **DRUG:** PF-00337210
- **DRUG:** PF-00337210

## Key facts

- **NCT ID:** NCT01105533
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2010-10
- **Final completion:** 2011-09
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2013-03-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01105533

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01105533, "A Dose Finding Study Of A New Medication, PF-00337210 That Will Possibly Decrease Blood Supply To Tumors". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01105533. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*